A comparative study of new biologic and small-molecule treatments for inflammatory bowel disease is slated to receive $2.4 million in grant funding from the Patient-Centered Outcomes Research Institute and the Crohn’s and Colitis Foundation (CCF).
According to a Healio report, the study will analyze agents including Janssen’s Stelara and Takeda’s Entyvio.
“Selecting the most effective treatment is incredibly important to our patients,” CCF’s IBD Plexus Senior Director Angela Dobes said in a statement. “This study will engage key stakeholders, most importantly patients, at each phase to ensure that the results provider patients, and their physicians, with strong evidence to support treatment decisions.”
The study will involved 180 American patients with a focus on patient-reported outcomes collected via electronic surveys. Efficacy of therapies will be analyzed by investigators using real-world data.
